黄热病疫苗与含麻疹疫苗首剂覆盖率差异:全球数据来源案头综述
该案头综述基于2006至2016年34个黄热病疫苗纳入国家免疫规划且被EYE策略列为高风险的国家数据,比较黄热病疫苗与MCV1覆盖率差异。在30个纳入比较分析的国家中,美洲9国中6国、非洲21国中9国存在超过3个百分点的有意义差异。差异可能由目标人群和疫苗供应不同驱动,但不足以完全解释观察到的差异。
要点
- 美洲9国中6国黄热病疫苗与MCV1覆盖率差异达7-45个百分点。
- 非洲21国中9国两疫苗覆盖率差异达4-27个百分点。
- 26%国家报告MCV1缺货,47%国家报告黄热病疫苗缺货≥3年。
核心结论
- 在报告两疫苗覆盖率显著差异的国家,差异可能由目标人群和疫苗供应不同驱动,但不足以完全解释观察到的差异。
- 需进一步随访以识别若干国家覆盖率差异未能完全解释的可能原因。
研究设计与样本
- 案头综述,纳入34个国家(非洲22个、拉丁美洲12个),2006至2016年数据,均为黄热病疫苗国家引入且被EYE策略列为高风险的国家。
- 比较分析纳入30个国家,黄热病疫苗与MCV1覆盖率差异大于3个百分点视为有意义。
主要发现
- 美洲9国中6国(67%)两疫苗覆盖率存在有意义差异,范围为7-45%。
- 非洲21国中9国(43%)两疫苗覆盖率存在有意义差异,范围为4-27%。
- 9国(26%)报告MCV1缺货,16国(47%)报告2006至2016年间黄热病疫苗缺货达三年或以上。
关键数值与推荐
- 在30个纳入比较分析的国家中,黄热病疫苗与MCV1覆盖率差异大于3个百分点视为有意义。
- WHO建议在黄热病流行区黄热病疫苗与MCV1同时接种。
临床怎么用
- 在黄热病流行区应关注黄热病疫苗与MCV1覆盖率差异,核查目标人群定义与疫苗供应情况。
- 对报告缺货的国家,需评估缺货对两疫苗覆盖率差异的潜在影响。
局限性
- 差异可能由目标人群和疫苗供应不同驱动,但不足以完全解释观察到的差异。
- 需进一步随访以识别若干国家覆盖率差异未能完全解释的可能原因。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The strategy to Eliminate Yellow Fever Epidemics (EYE) is a global initiative that includes all countries with risk of yellow fever (YF) virus transmission. Of these, 40 countries (27 in Africa and 13 in the Americas) are considered high-risk and targeted for interventions to increase coverage of YF vaccine. Even though the World Health Organization (WHO) recommends that YF vaccine be given concurrently with the first dose of measles-containing vaccine (MCV1) in YF-endemic settings, estimated coverage for MCV1 and YF vaccine have varied widely. The objective of this study was to review global data sources to assess discrepancies in YF vaccine and MCV1 coverage and identify plausible reasons for these discrepancies. METHODS: We conducted a desk review of data from 34 countries (22 in Africa, 12 in Latin America), from 2006 to 2016, with national introduction of YF vaccine and listed as high-risk by the EYE strategy. Data reviewed included procured and administered doses, immunization schedules, routine coverage estimates and reported vaccine stock-outs. In the 30 countries included in the comparitive analysis, differences greater than 3 percentage points between YF vaccine and MCV1 coverage were considered meaningful. RESULTS: In America, there were meaningful differences (7-45%) in coverage of the two vaccines in 6 (67%) of the 9 countries. In Africa, there were meaningful differences (4-27%) in coverage of the two vaccines in 9 (43%) of the 21 countries. Nine countries (26%) reported MVC1 stock-outs while sixteen countries (47%) reported YF vaccine stock-outs for three or more years during 2006-2016. CONCLUSION: In countries reporting significant differences in coverage of the two vaccines, differences may be driven by different target populations and vaccine availability. However,these were not sufficient to completely explain observed differences. Further follow-up is needed to identify possible reasons for differences in coverage rates in several countries where these could not fully be explained.
引用
- Adrien N, Hyde TB, Gacic-Dobo M, et al. Differences between coverage of yellow fever vaccine and the first dose of measles-containing vaccine: A desk review of global data sources. Vaccine. 2019. PMID: 31266670. doi:10.1016/j.vaccine.2019.06.063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。